Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

BACKGROUND: Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 p...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:N Engl J Med
Päätekijät: Rosas, Ivan O., Bräu, Norbert, Waters, Michael, Go, Ronaldo C., Hunter, Bradley D., Bhagani, Sanjay, Skiest, Daniel, Aziz, Mariam S., Cooper, Nichola, Douglas, Ivor S., Savic, Sinisa, Youngstein, Taryn, Del Sorbo, Lorenzo, Cubillo Gracian, Antonio, De La Zerda, David J., Ustianowski, Andrew, Bao, Min, Dimonaco, Sophie, Graham, Emily, Matharu, Balpreet, Spotswood, Helen, Tsai, Larry, Malhotra, Atul
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Massachusetts Medical Society 2021
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7953459/
https://ncbi.nlm.nih.gov/pubmed/33631066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2028700
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia